New hope for tough colorectal cancer: Dual-Action drug targets resistant tumors
NCT ID NCT05426005
First seen May 29, 2026 · Last updated Jun 06, 2026 · Updated 2 times
Summary
This study tests a new drug called Cadonilimab in 28 people with advanced colorectal cancer that has a specific genetic feature (MSI-H or dMMR) and has stopped responding to standard immunotherapy. The drug targets two immune checkpoints (PD-1 and CTLA-4) to try to shrink tumors and control the disease. The main goal is to see how many patients are alive without their cancer getting worse after 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER STAGE IV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Sixth Affiliated Hospital of Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510655, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.